The recent data demonstrated that HL resistant for anti-PD1 immunotherapy was depleted in CD8+ T lymphocytes in tumor microenvironment and overexpressed the LAG-3 on CD4+ T lymphocytes. The gene discussed is PDCD1; the disease is neoplasm.